Classer les publications sur l'année

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Epidemiology of myasthenia gravis in France: A retrospective claims database study (STAMINA).

    SALORT-CAMPANA E, LAFORET P, DE POUVOURVILLE G, CROCHARD A, CHOLLET G, NEVORET C, EMERY C, BOUEE S, TARD C.

    Rev Neurol ; 2023;

  • SantĂ© Publique et EpidĂ©miologie

    Overview of organisational methods of primary cervical lesion screening programmes that use human papillomavirus testing.

    MARCHADIER A, BEZANNIER L,  BARRE-PIERREL S, MANCEAU A,  ABADIE A, DETOURNAY B.

    J Med Screen ; 2023;9691413231158932

  • Pharmaco-EpidĂ©miologie

    The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus.

    DE SEZE J, SUCHET L, MEKIES C, MANCHON E, LABAUGE P, GUENNOC AM, DEFER G, CLAVELOU P, CASTELNOVO G, BOURRE B, BENSA-KOSCHER C, AL KHEDR A, LE MAO J, VILLEMUR L, BOUEE S, LUCIANI L, VERMERSCH P.

    Neurol Ther ; 2023;12(2):351-369

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Epidemiology and disease burden of tuberous sclerosis complex in France: A population-based study based on national health insurance data

    FAGNANI F, LAURENDEAU C, DE ZELICOURT M, MARSHALL J.

    Epilepsia Open ; 2022;7(4):633-644

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017

    VERMERSCH P, SUCHET L, COLAMOARINO R, LAURENDEAU C, DETOURNAY B

    Mult Scler Relat Disord ; 2020;46:102521

  • Économie de la santĂ©

    Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims.

    DETOURNAY B, DEBOUVERIE M, PEREIRA O, SEYER D, SOUDAN M, COUROUVE L, JHOMA K, EPSTEIN J, GUILLEMIN F.

    Mult Scler Relat Disord ; 2019;36:101396

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Migraine burden and costs in france: a nationwide claims database analysis of triptan users.

    DONNET A, EMERY C, ALY S, ALLAF B, CAYRE F, MAHIEU N, GOURMELEN J, LEVY P, FAGNANI F.

    J Med Econ ; 2019;22(7):616-624

  • Économie de la santĂ©

    Multiple Source of Information to Characterize the Clinical, Therapeutic Management and Economic Burden of Patients with Multiple Sclerosis in France.

    EPSTEIN J, DETOURNAY B , GUILLEMIN F, DEBOUVERIE M, COUSIN M, TEHARD B, GAROT T, BITOUN L, SOUDANT M , DEPOORTERE PH, PAU D

    Value in Health ; 2017;20(9):a719

  • Économie de la santĂ©

    Effect of Multiple Sclerosis on Work Productivity

    DETOURNAY B, COUSIN M, GOURMELEN J, PAU D, PINGUET JM, TEHARD B, COZZONE D

    Value in Health ; 2017;20(9):a725

  • Économie de la santĂ©

    Effect of Multiple Sclerosis on Work Productivity

    DETOURNAY B, COUSIN M, GOURMELEN J, PAU D, PINGUET JM, TEHARD B, COZZONE D

    Value in Health ; 2017;20(9):a725

  • Économie de la santĂ©

    The Direct Cost of Patients With Multiple Sclerosis In France

    DETOURNAY B, COUSIN M, GOURMELEN J, L. BITOUN L, PAU D, COZZONE D, B. TEHARD B

    Value in Health ; 2017;20(9):a721

  • Économie de la santĂ©

    The Direct Cost of Patients With Multiple Sclerosis In France

    DETOURNAY B, COUSIN M, GOURMELEN J, L. BITOUN L, PAU D, COZZONE D, B. TEHARD B

    Value in Health ; 2017;20(9):a721

  • Pharmaco-EpidĂ©miologie

    Mortalité des sujets épileptiques vivant en institution spécialisée en France

    JALLON P, DE ZELICOURT M, CACHERA C, FAGNANI F, LAURENDEAU C

    Epilepsies ; 2008;20(3):179-187

  • Pharmaco-EpidĂ©miologie

    La mortalitĂ© observĂ©e Ă  trois ans dans l’enquĂȘte CAROLE

    JALLON P, DE ZELICOURT M, FAGNANI F, LAURENDEAU C, FAILLIOT M

    Epilepsies ; 2007;19(3):173-177

  • Pharmaco-EpidĂ©miologie

    Prise en charge de la douleur en mĂ©decine gĂ©nĂ©rale : l’Ă©tude EPIDOL

    EMERY C, GEORGE B, GOMAS JM, DELFIEU D, MIMAUD V, GUILLON P, FAGNANI F

    Douleurs ; 6(6):366-373